Bristol-Myers Squibb Announces U.S. FDA Approval of NULOJIX® (belatacept)

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food & Drug Administration has approved NULOJIX (belatacept).

Please see accompanying Full Prescribing Information, including Boxed WARNINGS at www.NULOJIX.com or www.bms.com.

NULOJIX is a registered trademark of Bristol-Myers Squibb.



CONTACT:

Bristol-Myers Squibb Company
Media:
Ken Dominski, 609-252-5251, [email protected]
Investors:
John Elicker, 609-252-4611, [email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.